The amount of documentation required in hospitals is enormous, yet much of this data remains unused or is only accessible to individual departments. dotbase medical GmbH wants to change this: its platform structures clinical data centrally and enables comprehensive use.

Which market am I targeting with my business idea? Who are my potential customers? And who are my competitors? The answers to these questions help scientists make insight-driven strategic decisions.

Ascenion's new portfolio company RareLink is pursuing the important goal of enabling personalized therapy management for myasthenia gravis through telemonitoring with its ‘MyaLink’ platform. The rare neurological autoimmune disease causes muscle weakness.

"We ensure that innovation finds its way into society. This has become a profession in the academic world."
Dr Christian A. Stein, General Manager of Ascenion GmbH, in the new promotional film of TransferAllianz

How can public research organisations (PROs) better support the creation of successful spin-offs – and do so faster? A new report by the National Associations Advisory Committee (NAAC) of ASTP offers valuable insights into this question.

HepaRegeniX GmbH, a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, recently announced the second closing and completion of a EUR 21.5 million financing round with the addition of Wellington Partners to its investor syndicate.

"We are trend agnostics – we deliberately take a countercyclical approach"

How do I write a business plan? What funding is available for my project? What else do I need to consider before and while founding a start-up? Scientists can find the answers to these and many more questions in Ascenion’s new digital Roadmap.

How standardised benchmarks can make start-ups in the life sciences sector more efficient and transparent

A record number of over 320 innovators from the international life-science community gathered in Munich for the 17th BioVaria, Europe’s premier event for showcasing commercially attractive inventions and start-ups.

Ascenion’s portfolio company Aptila Biotech has launched DIA-NN 2.0, an AI-powered software that simplifies and enhances proteomics data analysis. The commercial version of DIA-NN 2.0 is now available, meeting strong industry demand.

At the end of January, 27 technology transfer experts met at Ascenion to share their experiences and discuss key issues relating to spin-offs, the design of basic agreements and software-based inventions.

The new antibiotic BTZ-043 was discovered at the Leibniz-HKI in Jena, one of Ascenion’s partner institutes. It has been developed for clinical use in cooperation with the Tropical Institute at the LMU Hospital Munich, with funding from the German Center for Infection Research (DZIF).

Supported by its technology transfer partner Ascenion, Max Delbrück Center has entered into a licensing agreement with Kite providing the company with non-exclusive rights to use the transposon system for the genetic engineering of T cells.

TransferAllianz publishes guidelines for out-licensing IP in spin-offs from universities and research institutes in the life sciences

Prague, Czech Republic

Ankara, Turkey

Cologne, Germany